SG10201806381VA - Treatment of h. pylori infections using mtan inhibitors - Google Patents

Treatment of h. pylori infections using mtan inhibitors

Info

Publication number
SG10201806381VA
SG10201806381VA SG10201806381VA SG10201806381VA SG10201806381VA SG 10201806381V A SG10201806381V A SG 10201806381VA SG 10201806381V A SG10201806381V A SG 10201806381VA SG 10201806381V A SG10201806381V A SG 10201806381VA SG 10201806381V A SG10201806381V A SG 10201806381VA
Authority
SG
Singapore
Prior art keywords
treatment
pylori
mtan
inhibitors
pylori infections
Prior art date
Application number
SG10201806381VA
Other languages
English (en)
Inventor
Vern Schramm
Keith Clinch
Shivali Gulab
Original Assignee
Albert Einstein College Medicine Inc
Victoria Link Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Medicine Inc, Victoria Link Ltd filed Critical Albert Einstein College Medicine Inc
Publication of SG10201806381VA publication Critical patent/SG10201806381VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201806381VA 2014-02-12 2015-02-06 Treatment of h. pylori infections using mtan inhibitors SG10201806381VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461938755P 2014-02-12 2014-02-12

Publications (1)

Publication Number Publication Date
SG10201806381VA true SG10201806381VA (en) 2018-08-30

Family

ID=53800544

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201806381VA SG10201806381VA (en) 2014-02-12 2015-02-06 Treatment of h. pylori infections using mtan inhibitors
SG11201606595RA SG11201606595RA (en) 2014-02-12 2015-02-06 Treatment of h. pylori infections using mtan inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201606595RA SG11201606595RA (en) 2014-02-12 2015-02-06 Treatment of h. pylori infections using mtan inhibitors

Country Status (12)

Country Link
US (2) US10118928B2 (enExample)
EP (1) EP3104707B1 (enExample)
JP (1) JP6512613B2 (enExample)
AU (1) AU2015217416B2 (enExample)
BR (1) BR112016019469B1 (enExample)
CA (1) CA2974916C (enExample)
HK (1) HK1232071A1 (enExample)
IL (1) IL247218B (enExample)
NZ (1) NZ724103A (enExample)
RU (1) RU2663803C2 (enExample)
SG (2) SG10201806381VA (enExample)
WO (1) WO2015123101A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6063571B2 (ja) 2012-08-07 2017-01-18 アルバート アインシュタイン カレッジ オブ メディシン,インコーポレイティド ヘリコバクター・ピロリ感染の治療
CN108794628A (zh) * 2018-05-28 2018-11-13 广东工业大学 一种抗幽门螺杆菌的卵黄抗体制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
AU2003245442B2 (en) * 2002-06-13 2009-02-05 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase IV inhibitors for the treatment of bacterial infections
US7553839B2 (en) 2002-08-21 2009-06-30 Industrial Research Limited 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
NZ533360A (en) 2004-06-04 2007-02-23 Ind Res Ltd Improved method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
WO2007016291A2 (en) 2005-07-27 2007-02-08 Albert Einstein College Of Medicine Of Yeshiva University Transition state structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases
ES2362805T3 (es) 2006-09-07 2011-07-13 Industrial Research Limited Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas.
US8383636B2 (en) * 2006-09-07 2013-02-26 Industrial Research Limited Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase
DK2114925T3 (da) 2006-12-22 2012-05-29 Ind Res Ltd Azetidin-analoger af nucleosidase- og phosphorylase-inhibitorer
WO2008115531A1 (en) * 2007-03-21 2008-09-25 Novacea, Inc. Prevention and treatment of infectious conditions with active vitamin d compounds or mimics thereof
WO2010033236A2 (en) * 2008-09-22 2010-03-25 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for treating bacterial infections by inhibiting quorum sensing
JP5861243B2 (ja) 2009-07-17 2016-02-16 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 5’−メチルチオアデノシンホスホリラーゼ及びヌクレオシダーゼの3−ヒドロキシピロリジン阻害剤
US9290501B2 (en) * 2010-11-29 2016-03-22 Albert Einstein College Of Medicine, Inc. Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
JP6063571B2 (ja) 2012-08-07 2017-01-18 アルバート アインシュタイン カレッジ オブ メディシン,インコーポレイティド ヘリコバクター・ピロリ感染の治療
US9522159B2 (en) 2012-09-11 2016-12-20 Albert Einstein College Of Medicine, Inc. Treatment and prevention of P. aeruginosa infections using coformycin analogs
WO2014073989A1 (en) 2012-11-12 2014-05-15 Callaghan Innovation Research Limited Salt and polymorphic forms of (3r,4s)-l-((4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(mtdia)

Also Published As

Publication number Publication date
CA2974916A1 (en) 2015-08-20
AU2015217416B2 (en) 2018-10-04
WO2015123101A1 (en) 2015-08-20
RU2016136533A3 (enExample) 2018-06-06
JP2017506238A (ja) 2017-03-02
RU2663803C2 (ru) 2018-08-09
US10118928B2 (en) 2018-11-06
IL247218A0 (en) 2016-09-29
NZ724103A (en) 2020-07-31
BR112016019469A2 (pt) 2018-07-24
CA2974916C (en) 2022-05-31
US20190016730A1 (en) 2019-01-17
EP3104707A1 (en) 2016-12-21
AU2015217416A1 (en) 2016-09-29
US20170166571A1 (en) 2017-06-15
SG11201606595RA (en) 2016-09-29
EP3104707B1 (en) 2020-07-15
US10294233B2 (en) 2019-05-21
HK1232071A1 (zh) 2018-01-05
IL247218B (en) 2020-06-30
EP3104707A4 (en) 2017-12-13
BR112016019469B1 (pt) 2022-12-06
JP6512613B2 (ja) 2019-05-15
RU2016136533A (ru) 2018-03-13

Similar Documents

Publication Publication Date Title
MX2017015473A (es) Tratamiento contra el cancer por manipulacion de la microflora comensal.
MD4801B1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
TW201613636A (en) Methods of treating Alzheimer's Disease
GB201516504D0 (en) Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
ZA202211665B (en) Ammonia oxidizing bacteria for treatment of acne
PL3634444T3 (pl) Kompozycje do zastosowania w leczeniu Helicobacter pylori
MX2019000677A (es) Células miméticas de células b.
MX2017000306A (es) Metodos para tratar hipotension.
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
MX2017013047A (es) Tratamiento de dolor.
HK1232071A1 (zh) 使用mtan抑制剂治疗h.pylori感染
WO2015027121A3 (en) Cancer treatment
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
WO2016135456A3 (en) A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy
WO2015134603A3 (en) Methods for treating cancer
WO2014135878A3 (en) Methods for treating cells with immunosuppressants to enhance their immunosuppressive potency
WO2016012632A9 (es) Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida
MA40574A (fr) Traitement de maladies fibrotiques
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
WO2016025533A3 (en) Compositions and methods for treating synucleinopathies
HK1240079A1 (en) Method for treating hyperhidrosis
UA86338U (ru) Способ лечения беременных с гестационным диабетом